Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Reporting period and context: The Form 8-K reports events occurring on November 30, 2019, with related announcements and filings dated December 2, 2019. The company is a Delaware corporation listed on Nasdaq under the symbol PHAT.
Financial and Operating Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial results.
Material Changes
- Chris Slavinksy resigned from the Board and all committees on November 30, 2019, in connection with his departure from Takeda Pharmaceutical Company Limited.
- Asit Parikh, M.D., Ph.D., a Takeda senior executive, was appointed as a Class II director to fill the vacancy. His initial term expires at the 2021 annual meeting.
- Following Mr. Slavinksy’s resignation, the Audit Committee no longer had the minimum three independent directors required by Nasdaq Listing Rule 5605(c)(2)(A).
- The company notified Nasdaq that it will use the applicable cure period and add an independent Audit Committee member by the earlier of the 2020 annual meeting or November 30, 2020.
- Terrie Curran became Chief Executive Officer, replacing David Socks, as part of a previously announced leadership transition.
- David Socks became interim Chief Financial Officer, principal financial officer, and principal accounting officer, replacing Aditya Kohli in those filing roles. Both Ms. Curran and Mr. Socks remain Board members.
- Eckhard Leifke, M.D., was appointed Chief Medical Officer; Joseph Hand, J.D., Chief Administrative Officer; and Larry Miller, J.D., General Counsel.
Guidance, Risks, and Unusual Items
- The company faces a temporary Nasdaq governance compliance deficiency related to the composition of its Audit Committee. Failure to cure the deficiency within the permitted period could affect its continued listing, although no delisting determination is reported in this filing.
- Compensation arrangements for Ms. Curran and Mr. Socks were unchanged from those disclosed in the company’s October 2019 prospectus.
- Dr. Parikh will not receive cash or equity compensation under the company’s non-employee director compensation program.
- The filing provides no financial guidance, operating outlook, litigation update, or contingency amounts.
Investor Verification Items
- Verify that the company added an independent Audit Committee director by the applicable Nasdaq deadline and maintained continued listing compliance.
- Review subsequent filings for the effectiveness and permanence of the CEO and interim CFO appointments.
- Confirm subsequent board composition, committee assignments, and any compensation changes.
- Review later financial filings for liquidity, cash runway, development spending, and other financial metrics not included in this 8-K.